Earnings Report

Discussion in 'Valeant Pharmaceuticals' started by Anonymous, Feb 27, 2014 at 9:29 AM.

Tags: Add Tags
  1. Anonymous

    Anonymous Guest

    Remember this is reported in weaker Canadian Dollars!
     

  2. Anonymous

    Anonymous Guest

    Wrong. Filings with the SEC are in $US. And quit double-posting.

    There are lots of things Valeant does wrong - you don't need to make shit up.
     
  3. Anonymous

    Anonymous Guest

    LOL. What the?
    You sure seem defensive.
    Let us look at the bottom line here...
    VRX is fucked.
    NO QUESTION ABOUT IT.
     
  4. Anonymous

    Anonymous Guest

    This time round it seemed that everything except aesthetics grew solidly in q2. Are things looking up?
     
  5. Anonymous

    Anonymous Guest

    Uh, the earnings call was resoundingly positive. The stock dropped to adequately price in the revised earnings after the sale of products to Nestlé. If you do the math, the stick now reflects the new multiple, but every investment house that called in questions was positive, and they all seemed to like Valeant market position even without the Aquisition(which will still likely happen).

    Enough hyperbole on this site. Disgruntled former employees and scared allergan reps. Bottom line, VRX is in great shape with or without allergan
     
  6. Anonymous

    Anonymous Guest

    yeah way to gooooooooooooooooo

    enough whining on this site about valeant. go talk about another company's problems
     
  7. Anonymous

    Anonymous Guest

    Completely agree.
     
  8. Anonymous

    Anonymous Guest

    Oh Please!!!!


    Your Q2 numbers are nonsense and you will soon be made aware of that fact. How can any of you at VRX sit comfortably when you have the leadership you do at the helm?????
     
  9. Anonymous

    Anonymous Guest

    go read the May presentations with the resumes of the general managers across the world. this team hands down beat any other around the world for smarts, energy and drive. The business is healthy and growing.
     
  10. Anonymous

    Anonymous Guest

    You must have posted under the wrong company--this is Valeant's board.
     
  11. Anonymous

    Anonymous Guest

    Because our stock is up 800% since 2009. Because our three year stock chart goes up at a 45 degree angle. Because our executive management team thinks we are worthy of a company stock plan which allows us to benefit when the company wins. Because our CEO is the Prince of Wall Street. And because we are about to put Allergan in our back pocket. Those are just a few reasons I sleep like a baby at night.
     
  12. Anonymous

    Anonymous Guest

    echo that 100 times
     
  13. Anonymous

    Anonymous Guest

    I see 'cry baby' Ackman has put in an appearance!
     
  14. Anonymous

    Anonymous Guest

    can you say McKinsey and Enron?
     
  15. Anonymous

    Anonymous Guest





    This post is laughable! Let's see if you think all this when VRX breaks apart.
     
  16. Anonymous

    Anonymous Guest

    http://finance.yahoo.com/news/valeant-vrx-moving-average-crossover-122806523.html

    Valeant Pharmaceuticals Intl Inc (VRX) could be a stock to avoid from a technical perspective, as the firm is seeing unfavorable trends on the moving average crossover front. Recently, the 50 Day Moving Average for VRX broke out below the 200 Day Simple Moving Average, suggesting short-term bearishness.

    This has already started to take place, as the stock has moved lower by 6.2% in the past four weeks. And with the recent moving average crossover, investors have to think that more unfavorable trading is ahead for VRX stock.

    If that wasn’t enough, Valeant isn’t looking too great from an earnings estimate revision perspective either. It appears as though many analysts have been reducing their earnings expectations for the stock lately, which is usually not a good sign of things to come.

    Consider that in the last 30 days, 1 estimate has been reduced, while none has moved higher. Add this in to a similar move lower in the consensus estimate, and there is plenty of reason to be bearish here.

    That is why we currently have a Zacks Rank #4 (Sell) on this stock and are looking for it to underperform in the weeks ahead. So either avoid this stock or consider jumping ship until the estimates and technical factors turn around for VRX.
     
  17. Anonymous

    Anonymous Guest

    Weak article
     
  18. Anonymous

    Anonymous Guest

    Its posts like this that kill me. Of course I wouldn't "think all this" if VRX were to "break apart."
     
  19. Anonymous

    Anonymous Guest

    JPMorgan begs to differ
     
  20. Anonymous

    Anonymous Guest



    Post said "when" not were! Comprehend much! Stupid ass Valeant bot!